NCT04240522 Prospective Longitudinal Observational Research in Atopic Dermatitis
| NCT ID | NCT04240522 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Zurich |
| Condition | Atopic Dermatitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2017-04-04 |
| Primary Completion | 2031-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2017-04-04 with a primary completion date of 2031-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atopic dermatitis (AD) is a frequent chronic relapsing inflammatory skin disorder, characterized by intensely itchy eczema. AD usually starts within the first 2 years of life. In 30 - 60% of children, inflammation spreads onto other body surfaces such as the gastrointestinal tract, the respiratory tract, and the conjunctives within a few years. This sequence is called atopic march. Atopic dermatitis and associated atopic diseases are more frequent in families, suggesting a genetic predisposition. However, the underlying factors such as genetic phenotype, environmental factors, or life style which cause or worsen an existing allergic disease are not understood yet. Affected people suffer from recurrent flares that result in significantly impaired quality. This study will collect clinical and laboratory data to elucidate immunotolerance and preventiv stategies with the aim to develop new and individual treatment options of atopic diseases.
Eligibility Criteria
Inclusion Criteria: * Age 0 - 85 years * Diagnosis of AD and/or another disease of the atopic group (i.e. allergic rhinitis, allergic asthma, food allergy) * The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated The inclusion criteria for healthy controls in this study are as follows: * Age 0 - 85 years * No diagnosis or history of allergic disease * The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated Written consent will be obtained after detailed information of the study was given to the participant. Exclusion Criteria \- Unable to give consent or refusal to participate in the study
Frequently Asked Questions
Who can join the NCT04240522 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, up to 85 Years, studying Atopic Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04240522 currently recruiting?
Yes, NCT04240522 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Zurich to inquire about joining.
Where is the NCT04240522 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT04240522 clinical trial?
NCT04240522 is sponsored by University of Zurich. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.